Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORA: Docetaxel vs Docetaxel + Radium-223 in mCRPC
2024-513867-19-00Phase 3Authorised
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 4
01
Overview
Phase 3, randomised trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall survival (OS). Planned start Oct 2024; status: authorised.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-513867-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513867-19-00.